Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Seymour JF,Davids MS,Pagel JM et al.
Key Points:
Higher activity of Bcl2 in patients with R/R CLL/SLL.
56 pts enrolled in cohorts at doses from 150 to 1200 mg. 22 pts discontinued ABT-199 b/o AEs(n=8).
Overall RR CLL 84% (20% CR/CRi); RR in patients with 17p deletion and fludarabine refractory disease 82% and 78% respectively.
Implications:
- ABT-199 seems promising, producing overall RR of ~80% in relapse refractory setting even with high risk disease.
View the original abstract on the ASH website.
